Lead Product(s) : Colchicine,Ropivacaine Hydrochloride
Therapeutic Area : Rheumatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PK MED Gets FDA Clearance to Initiate Clinical Program for PKM-01 in Gout Flares
Details : PKM-01 (colchicine) is an intra-articular combination of a fast-acting anesthetic and a controlled-release form of a powerful anti-inflammatory agent (colchicine). Being evaluated for gout flares.
Product Name : PKM-01
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : Colchicine,Ropivacaine Hydrochloride
Therapeutic Area : Rheumatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CPL-01 is an extended-release injectable formulation of Naropin® (ropivacaine hydrochloride), which is a member of the amino amide class of local anesthetics indicated for the production of local or regional anesthesia for surgery and acute pain managem...
Product Name : CPL-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Lotus Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRF-110 (ropivacaine) is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended postoperative analgesia.
Product Name : PRF-110
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Lotus Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the dose currently planned as the to-be marketed dose, 14 subjects who received CPL-01 showed a mean AUC through 72 hours of wWOCF adjusted NRS-A of 286.8, showing a trend towards significance against the 13 subjects who received placebo.
Product Name : CPL-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2022
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRF-110 is based on the local anesthetic ropivacaine, targeting post-operative pain relief market. PRF-110 is an oil-based, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-oper...
Product Name : PRF-110
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TLC Reports Early Completion of Patient Enrollment in TLC590 Phase II
Details : The randomized, double-blind, comparator- and placebo-controlled study will evaluate the analgesic efficacy and safety of TLC590 for postsurgical pain management in patients following bunionectomy.
Product Name : TLC590
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2020
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Maxim Group LLC
Deal Size : $25.0 million
Deal Type : Public Offering
Israeli Pain Relief Biotech PainReform Files for a $25 million US IPO
Details : The company's lead candidate and first product, PRF-110, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. Company plans to initiate two Phase 3 trials for PRF-110 soon after the closing of this offering.
Product Name : PRF-110
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2020
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Maxim Group LLC
Deal Size : $25.0 million
Deal Type : Public Offering
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results show that TLC590 demonstrated greater reductions in pain than both placebo and bupivacaine through 168 hours. TLC590 a non-opioid, proprietary BioSeizer sustained release formulation of ropivacaine.
Product Name : TLC590
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2020
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
